Efficacy of lithium as an adjunctive therapy to antiretroviral regimens in treating HIV associated Mild Neurocognitive Disorder

niversity of Melbourne0 个研究点目标入组 100 人开始时间: 2012年7月6日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Participants must meet all of the following inclusion criteria to participate in this study:
•1. HIV-positive
•2. Age 18-65 years
•3. Diagnosis of Asymptomatic Neurocognitive Impairment or Mild Neurocognitive Disorder
•4. Karnofsky score > 49
•5. Stable cART for at least 12 weeks prior to study entry
•6. English fluency

•All participants meeting any of the following exclusion criteria at baseline will be excluded from study participation:
•1. Current bipolar disorder, major depressive disorder, schizophrenia
•2. Creatinine > 110 umol/L or Urea >8.0 mmol/L (i.e. significant renal disease)
•3. Clinically significant cardiovascular, renal, or thyroid disease
•4. Neurologic diseases other than HIV-associated neurocognitive impairment that are known to affect cognition
•5. Pregnant or nursing women
•6. Untreated or unstable psychiatric illness
•7. Severe pre-morbid psychiatric illness
•8. Active alcohol or drug abuse
•9. Active, symptomatic, opportunistic infections
•10. Absolute neutrophil count < 500 cells/micro litres
•11. Currently taking precautionary or prohibited medications

发起方

niversity of Melbourne